Washington Trust Advisors, Inc. Aldeyra Therapeutics, Inc. Transaction History
Washington Trust Advisors, Inc.
- $1.06 Billion
- Q1 2024
A detailed history of Washington Trust Advisors, Inc. transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Washington Trust Advisors, Inc. holds 3,800 shares of ALDX stock, worth $12,122. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,800
Previous 3,800
-0.0%
Holding current value
$12,122
Previous $13,000
7.69%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding ALDX
# of Institutions
106Shares Held
35.4MCall Options Held
104KPut Options Held
88.1K-
Perceptive Advisors LLC New York, NY8.59MShares$27.4 Million0.59% of portfolio
-
Knoll Capital Management, LLC Miami, FL5.48MShares$17.5 Million11.18% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.87MShares$12.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.31MShares$10.6 Million0.0% of portfolio
-
Kennedy Capital Management, Inc. St Louis, MO1.32MShares$4.2 Million0.09% of portfolio
About Aldeyra Therapeutics, Inc.
- Ticker ALDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,323,100
- Market Cap $186M
- Description
- Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...